{
    "nct_id": "NCT03128008",
    "official_title": "Phase II Study of Accelerated and Adaptive Radiation Therapy for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "inclusion_criteria": "1. Histologic/cytologic documentation of non-small cell lung cancer (NSCLC)\n2. Unresectable stage II, IIIA, or IIIB disease\n3. Zubrod/ECOG performance status 0-1\n4. Weight loss < 10% in preceding 3 months prior to diagnosis\n5. Adequate organ function defined as the following\n6. Absolute neutrophil count of ≥ 1,500 and platelet count ≥ 100,000\n7. Cockcroft calculated creatinine clearance of ≥ 45 ml/min or 1.5 x the upper limit of normal (ULN)\n8. A total bilirubin ≤ 1.5 ULN, aspartate aminotransferase (AST) ≤ 2.0 x ULN\n9. ≥ 18 years of age.\n10. Negative pregnancy test in women of child-bearing potential\n11. Signed study-specific informed consent.\n12. No prior chemotherapy or radiotherapy for NSCLC\n13. No prior mediastinal or thoracic radiation\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Prior thoracic irradiation.\n2. Medical contraindications to thoracic irradiation.\n3. Pre-existing sensory neuropathy of grade ≥ 2\n4. Pleural effusion: when pleural fluid is visible on both CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative.\n\n   Patients with effusions that are minimal (i.e. not visible on chest x-ray) or that are too small to safely tap are eligible\n5. Patients with contralateral hilar involvement",
    "miscellaneous_criteria": ""
}